Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review

Abstract Background The overall incidence of pituitary apoplexy among patients with pituitary adenoma ranges from 0.6% to 7.0%, although many cases likely go undiagnosed. Several precipitating factors have been identified, and a small number of case reports have suggested an association between immu...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Chiaki Imai, Masashi Uchida, Koji Takahashi, Izumi Ohno, Yuichi Takiguchi, Itsuko Ishii
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2026-03-01
Serija:	Journal of Pharmaceutical Health Care and Sciences
Teme:	Pituitary apoplexy Immune checkpoint inhibitors Ipilimumab Nivolumab Adverse events Melanoma
Online dostop:	https://doi.org/10.1186/s40780-026-00564-4
Oznake:	Označite Brez oznak, prvi označite!